PORTFOLIO

Most of the work we do is confidential and can not be shared. However, here are some of the publications and projects that are publically available that we have provided medical writing support for.

Get in Touch

Learn more

cardiovascular / pulmonary hypertension

Di Scala L, et al. Adjusting overall survival estimates of macitentan in pulmonary arterial hypertension after treatment switching: Results from the SERAPHIN study. Adv Ther. 2022;39(9):4346-4358.
Review: Clozel M. Aprocitentan and the endothelin system in resistant hypertension. Can J Physiol Pharmacol. 2022;100(7):573-583.

artificial intelligence

DuBrock H, et al. An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension. Eur Respir Journal 2024.
Salehi M, et al. Artificial intelligence-based echocardiography assessment to detect pulmonary hypertension. ERJ Open Res 2024.

fact checking

Here are just a few examples from over 200 articles that have been fact checked:

Insomnia

Review: Roch C, et al. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology. 2021; 238:2693-2708.
Book: Steiner MA, Yanagisawa M, Clozel M. The orexin system. Basic science and role in sleep pathology, 2021; ISBN: 978-3-318-06843-6; e-ISBN: 978-3-318-06844-3.
Steiner MA, Seboek Kinter D. Die Behandlung chronischer Schlaflosigkeit durch pharmakologische Hemmung des Orexin-Systems. Sonderausgabe Gesellschaftspolitische Kommentare Nr. 2/22 – November 2022 – Seite 16 [Translated in to German]
Mignot E, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurology 2022; 21(2):125-139.
Fietze I, et al. Efficacy and safety of daridorexant in older and younger adults with insomnia disorder: A secondary analysis of a randomised placebo-controlled trial. Drugs Aging 2022; 39:795–810.
Kunz D, et al. Long-term safety and tolerability of daridorexant in patients with insomnia disorder. CNS Drugs 2023; 37:93–106.
Steiner MA, et al. Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats. J Psychopharmacol. 2023;37(12):1249-1260.
Luyet PP, et al. Understanding daytime functioning in insomnia: responder and correlation analyses in patients treated with daridorexant. Sleep Science Practice 2023; 7:7.
Luyet PP, et al. Dose-response of daridorexant in insomnia disorder: an analysis of Phase 2 and 3 studies. Sleep Medicine 2024.